Hey, i just found an interesting article on yahoo health search. The article touches on natural fat loss.
The article says:
”
Even if the recession prompts some patients to delay weight-loss surgery, executives at St. Paul-based Synovis Life Technologies are bullish about the prospects for their top product — a buttress made of biomaterials that is used in the procedures.
That’s because after posting strong financial results for its fourth quarter, Synovis said Wednesday it is expanding its sales force by up to 15 people this year.
“With more feet on the street, we will be growing more,” said Richard Kramp, the company’s chief executive officer, in an interview. “So if there is some impact (from the recession), we certainly will be blunting it.”
As the economy has slowed, hospitals across the country have reported a decline in patients seeking elective procedures. In part that’s because many Americans now must pay larger deductibles for the care they receive — a cost-sharing technique in many employer-sponsored health plans.
During a conference call with investors Wednesday, Kramp acknowledged that weight-loss surgeries could be considered “somewhat elective.” And he spelled out two theories to explain why procedure volumes could be limited in coming quarters.
Recovery from weight-loss surgery can take a patient away from work for a week or two, Kramp said. But some people might not want to be away from their jobs that long at a time when many firms are looking for places to make cuts.
Health plans typically cover the cost of weight-loss surgery. But the number
of procedures — which can cost between $20,000 and $30,000 — could be reduced if more people lose health insurance because of layoffs, Kramp said.
While acknowledging the theories, Kramp said he wasn’t worried about the recession’s impact at Synovis.
“I think this will be small,” he said. “We don’t see this as a big effect.”
Synovis employs about 225 people, including about 180 in St. Paul. The added jobs in the sales force will not boost local employment, Kramp said.
For the quarter ended Oct. 31, Synovis reported sales of $12.7 million — a 24 percent increase over sales of $10.3 million during the same quarter last year. Net income came in at $1.9 million or 15 cents per share — up 23 percent from a profit of $1.6 million during the same quarter last year.
Analysts surveyed by Thomson Reuters were expecting earnings of 14 cents per share on revenue of $13.8 million.
Synovis shares closed Wednesday at $14.45, up $1.15, or 8.6 percent.
Christopher Snowbeck can be reached at 651-228-5479.”
Popularity: 5% [?]
Entries (RSS)